biliary tract cancer (Cancer)
Information
- Disease name
- biliary tract cancer
- Disease ID
- DOID:4607
- Description
- "A hepatobiliary system cancer that results_in malignant growth located_in the gallbladder or located_in the bile duct." [url:http\://en.wikipedia.org/wiki/Biliary_tract_cancer]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04329429 | Active, not recruiting | Phase 2 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | August 24, 2020 | June 30, 2024 |
| NCT03785873 | Active, not recruiting | Phase 1/Phase 2 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | May 22, 2019 | May 2025 |
| NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
| NCT03639935 | Active, not recruiting | Phase 2 | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | March 28, 2019 | February 2025 |
| NCT04203160 | Active, not recruiting | Phase 1/Phase 2 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | June 23, 2020 | May 2025 |
| NCT06074029 | Active, not recruiting | Phase 1/Phase 2 | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | December 1, 2021 | August 1, 2024 |
| NCT05297903 | Active, not recruiting | Phase 2 | XmAb20717 in Advanced Biliary Tract Cancers | April 11, 2022 | December 31, 2024 |
| NCT02908048 | Active, not recruiting | Extracellular RNA Markers of Liver Disease and Cancer | July 2014 | July 2026 | |
| NCT05156788 | Active, not recruiting | Phase 2 | Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | December 12, 2021 | October 1, 2025 |
| NCT02711553 | Active, not recruiting | Phase 2 | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | May 19, 2016 | December 31, 2025 |
| NCT03631173 | Active, not recruiting | N/A | Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy | April 2, 2019 | December 31, 2025 |
| NCT04660929 | Active, not recruiting | Phase 1 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | February 2, 2021 | December 31, 2024 |
| NCT03044587 | Active, not recruiting | Phase 2 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer | January 24, 2018 | January 2025 |
| NCT01308840 | Completed | Phase 2 | Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer | December 2010 | January 2013 |
| NCT01530503 | Completed | Phase 2 | Second Line Therapy in Advanced Biliary Tract Cancer | November 2011 | October 2013 |
| NCT01572324 | Completed | Phase 2 | Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas | March 2012 | April 2016 |
| NCT01589328 | Completed | N/A | Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB | March 15, 2012 | June 30, 2017 |
| NCT01657383 | Completed | Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery | April 2012 | February 2017 | |
| NCT01713387 | Completed | Phase 1 | A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy | April 2012 | March 2017 |
| NCT01815307 | Completed | Phase 2 | Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer | January 2013 | December 2017 |
| NCT01861483 | Completed | Vessel Resection and Reconstruction of Biliary Tract Cancers | March 2013 | March 2014 | |
| NCT01899976 | Completed | N/A | X-MAS Biliary Study With Covered Biliary Stent | August 2013 | November 13, 2017 |
| NCT01917617 | Completed | Phase 2 | Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer | May 22, 2013 | July 7, 2016 |
| NCT01926236 | Completed | Phase 3 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers | February 2014 | January 2019 |
| NCT02002806 | Completed | N/A | Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control | January 2012 | June 2019 |
| NCT02102984 | Completed | N/A | Covered Versus Uncovered Biliary Stents for Biliary Malignancies | April 2014 | December 2015 |
| NCT02182778 | Completed | Phase 3 | GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer | July 9, 2014 | April 16, 2018 |
| NCT02346032 | Completed | Phase 2 | Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma | June 30, 2015 | October 13, 2016 |
| NCT02351765 | Completed | Phase 1 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers | January 2016 | March 2019 |
| NCT02433639 | Completed | Phase 2 | Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer | April 2015 | October 2017 |
| NCT02443324 | Completed | Phase 1 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | July 29, 2015 | April 12, 2022 |
| NCT02489422 | Completed | N/A | Programs To Support You During Chemotherapy | August 2016 | January 2020 |
| NCT00123825 | Completed | Phase 2 | Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer | July 2002 | October 2007 |
| NCT00142480 | Completed | Phase 2 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | December 2004 | April 2011 |
| NCT00339560 | Completed | A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China | May 16, 1997 | May 21, 2008 | |
| NCT00361231 | Completed | Phase 2 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | May 2006 | August 2012 |
| NCT00380588 | Completed | Phase 2 | Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer | September 2006 | October 2008 |
| NCT00423254 | Completed | Phase 1 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | February 2007 | November 2009 |
| NCT00753675 | Completed | Phase 2 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer | October 2008 | September 2012 |
| NCT00832689 | Completed | Phase 2 | Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer | June 2008 | March 2010 |
| NCT01284413 | Completed | Phase 1/Phase 2 | Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer | December 2010 | August 2013 |
| NCT01291615 | Completed | Phase 1 | Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer | December 2010 | May 2013 |
| NCT01294085 | Completed | Case Series Study of Biliary Tract Cancer Patients in Japan | November 2010 | August 2011 | |
| NCT01297998 | Completed | Phase 1 | A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy | January 2011 | June 2013 |
| NCT02579616 | Completed | Phase 2 | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | October 23, 2015 | February 27, 2019 |
| NCT02586987 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | December 28, 2015 | September 20, 2019 |
| NCT02670265 | Completed | N/A | Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions | June 2012 | February 2014 |
| NCT02773459 | Completed | Phase 1/Phase 2 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | April 2016 | January 7, 2019 |
| NCT02829918 | Completed | Phase 2 | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | October 5, 2016 | May 24, 2023 |
| NCT02966821 | Completed | Phase 2 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | January 3, 2017 | November 30, 2018 |
| NCT02988635 | Completed | Phase 3 | Early Palliative Care on Quality of Life of Advanced Cancer Patients | November 2014 | November 2016 |
| NCT03079427 | Completed | Phase 2 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | May 15, 2017 | November 15, 2022 |
| NCT03093870 | Completed | Phase 2/Phase 3 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | July 4, 2017 | April 17, 2020 |
| NCT03110328 | Completed | Phase 2 | Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes | February 7, 2018 | March 24, 2022 |
| NCT03231176 | Completed | Phase 2 | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | December 19, 2017 | April 13, 2020 |
| NCT03260712 | Completed | Phase 2 | Pembrolizumab in Biliary Tract Cancer | January 7, 2020 | August 31, 2023 |
| NCT03411200 | Completed | N/A | Patient Activation Through Counseling, Exercise and Mobilization | April 4, 2018 | July 1, 2020 |
| NCT03486678 | Completed | Phase 2 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | February 10, 2018 | November 30, 2020 |
| NCT03531320 | Completed | Phase 1/Phase 2 | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase | August 6, 2018 | December 29, 2020 |
| NCT03613168 | Completed | Phase 2 | Trastuzumab in HER2-positive Biliary Tract Cancer | June 1, 2019 | January 4, 2021 |
| NCT03778593 | Completed | Phase 2 | FOLFIRINOX for 2nd-line Treatment of BTC | March 1, 2019 | January 14, 2021 |
| NCT03796429 | Completed | Phase 2 | A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer | December 17, 2018 | March 30, 2022 |
| NCT03830606 | Completed | Phase 2 | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | March 23, 2016 | September 1, 2019 |
| NCT03833661 | Completed | Phase 2 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | March 26, 2019 | September 30, 2022 |
| NCT03937895 | Completed | Phase 1/Phase 2 | Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer | December 3, 2019 | June 8, 2021 |
| NCT04338685 | Completed | Phase 1 | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | July 16, 2020 | January 9, 2023 |
| NCT04642664 | Completed | Phase 2 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | December 1, 2018 | January 1, 2021 |
| NCT04656249 | Completed | Phase 2 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer | January 1, 2018 | May 1, 2021 |
| NCT04677504 | Completed | Phase 2 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | February 23, 2021 | August 25, 2023 |
| NCT04720131 | Completed | Phase 2 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. | January 1, 2021 | May 30, 2023 |
| NCT04776837 | Completed | Predicting Disease Progression and/or Recurrence in Cancer | May 15, 2019 | November 19, 2021 | |
| NCT04801719 | Completed | N/A | Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis | January 4, 2010 | December 31, 2019 |
| NCT05116891 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | September 22, 2021 | June 23, 2023 |
| NCT06222619 | Completed | Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma | January 30, 2020 | August 30, 2023 | |
| NCT04731220 | Enrolling by invitation | A Questionnaire Survey for Biliary Tract Cancers | July 14, 2020 | December 31, 2025 | |
| NCT06428409 | Not yet recruiting | Phase 2 | A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | June 19, 2024 | December 3, 2028 |
| NCT05723705 | Not yet recruiting | Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT) | April 2023 | December 2025 | |
| NCT05417230 | Not yet recruiting | Phase 2 | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | August 2022 | August 2025 |
| NCT06389500 | Not yet recruiting | Phase 2 | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | May 1, 2024 | May 1, 2028 |
| NCT06171321 | Not yet recruiting | N/A | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma | December 2023 | April 1, 2026 |
| NCT06431490 | Not yet recruiting | Phase 1/Phase 2 | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | July 2024 | December 2025 |
| NCT05487443 | Not yet recruiting | Phase 2/Phase 3 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | August 1, 2022 | August 30, 2024 |
| NCT06084689 | Not yet recruiting | Phase 2 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures | January 1, 2024 | January 1, 2027 |
| NCT06255262 | Not yet recruiting | Phase 1/Phase 2 | Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | February 15, 2024 | December 31, 2025 |
| NCT06109779 | Recruiting | Phase 3 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | December 4, 2023 | September 30, 2030 |
| NCT03673072 | Recruiting | Phase 3 | Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC | July 1, 2019 | November 2024 |
| NCT03695952 | Recruiting | A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors | July 1, 2018 | July 2024 | |
| NCT06178445 | Recruiting | Phase 2 | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer | April 17, 2024 | April 2028 |
| NCT03801083 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | February 19, 2019 | January 31, 2030 |
| NCT06202131 | Recruiting | Prospective Single-center Study About the Use of ctDNA in the Management of Patients With Tumors of the Gastrointestinal Tract | November 1, 2023 | November 1, 2028 | |
| NCT06451497 | Recruiting | Phase 1 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | May 22, 2024 | April 2027 |
| NCT03898895 | Recruiting | Phase 2 | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer | December 10, 2019 | November 2024 |
| NCT03924466 | Recruiting | Phase 2 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | April 1, 2019 | December 2024 |
| NCT06239194 | Recruiting | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | June 12, 2024 | February 2029 |
| NCT04318834 | Recruiting | N/A | Molecular Profiling of Advanced Biliary Tract Cancers | April 1, 2020 | January 2025 |
| NCT04401709 | Recruiting | Phase 3 | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | April 1, 2021 | March 30, 2025 |
| NCT04445532 | Recruiting | Hepatobiliary Tumors Tissue Samples Acquisition | October 11, 2020 | June 1, 2025 | |
| NCT04561453 | Recruiting | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | July 8, 2020 | July 1, 2025 | |
| NCT06282575 | Recruiting | Phase 3 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | June 30, 2024 | November 1, 2029 |
| NCT06293898 | Recruiting | Phase 1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | February 9, 2024 | August 24, 2027 |
| NCT06320301 | Recruiting | Phase 2 | Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | April 1, 2024 | June 1, 2026 |
| NCT06349044 | Recruiting | N/A | A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. | March 20, 2024 | December 31, 2025 |
| NCT04871321 | Recruiting | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | April 14, 2021 | December 31, 2024 | |
| NCT04896931 | Recruiting | New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC) | July 12, 2022 | September 2029 | |
| NCT04907643 | Recruiting | N/A | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | October 5, 2021 | March 2026 |
| NCT04935853 | Recruiting | Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study | May 23, 2022 | June 1, 2040 | |
| NCT04969835 | Recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | July 16, 2021 | June 30, 2023 |
| NCT05044065 | Recruiting | N/A | Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex) | May 1, 2022 | December 31, 2024 |
| NCT05052099 | Recruiting | Phase 1/Phase 2 | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer | October 2021 | June 2024 |
| NCT05065957 | Recruiting | Phase 2/Phase 3 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | March 29, 2022 | December 2026 |
| NCT05184400 | Recruiting | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer | January 1, 2015 | December 31, 2030 | |
| NCT05220046 | Recruiting | Phase 1 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer | April 10, 2023 | July 2025 |
| NCT05222971 | Recruiting | Phase 2 | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy | April 1, 2022 | December 30, 2025 |
| NCT05253053 | Recruiting | Phase 1/Phase 2 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | April 13, 2022 | December 2024 |
| NCT05254847 | Recruiting | Phase 2 | Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC | December 30, 2021 | December 2024 |
| NCT05429697 | Recruiting | Phase 2/Phase 3 | Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer | June 9, 2022 | June 8, 2026 |
| NCT05451043 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | July 5, 2023 | October 1, 2028 |
| NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
| NCT05506943 | Recruiting | Phase 2/Phase 3 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | January 9, 2023 | December 2025 |
| NCT05509478 | Recruiting | Phase 2 | Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma | August 20, 2022 | September 1, 2023 |
| NCT05512377 | Recruiting | Phase 2 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | November 25, 2022 | March 25, 2027 |
| NCT05520788 | Recruiting | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing | May 1, 2020 | December 31, 2025 | |
| NCT05667350 | Recruiting | AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) | February 28, 2022 | June 30, 2024 | |
| NCT05743959 | Recruiting | ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial | May 1, 2022 | December 30, 2025 | |
| NCT05771480 | Recruiting | Phase 3 | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | August 16, 2023 | March 17, 2026 |
| NCT05775159 | Recruiting | Phase 2 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | April 24, 2023 | November 25, 2026 |
| NCT05835778 | Recruiting | Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | June 7, 2023 | July 17, 2026 | |
| NCT05942807 | Recruiting | Observational Monocentric Study on Biliary Tract Cancer (BABEL) | May 15, 2021 | May 2026 | |
| NCT05994001 | Recruiting | Phase 1/Phase 2 | Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody | August 1, 2023 | August 1, 2026 |
| NCT05998447 | Recruiting | Phase 2 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | September 18, 2023 | October 2026 |
| NCT06017297 | Recruiting | Phase 2 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma | June 2024 | November 2026 |
| NCT06037980 | Recruiting | Phase 2/Phase 3 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | November 7, 2023 | January 2029 |
| NCT03475953 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | May 4, 2018 | December 31, 2025 |
| NCT03482102 | Recruiting | Phase 2 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | May 14, 2018 | October 2026 |
| NCT06139042 | Recruiting | Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers | November 1, 2023 | December 31, 2025 | |
| NCT04779151 | Suspended | Phase 2 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | April 7, 2021 | December 2027 |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT00630890 | Terminated | Phase 1 | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) | October 2007 | December 2008 |
| NCT01171755 | Terminated | Phase 2 | Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer | February 2008 | December 2009 |
| NCT04066491 | Terminated | Phase 2/Phase 3 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | September 20, 2019 | November 10, 2022 |
| NCT02992340 | Terminated | Phase 1/Phase 2 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | December 13, 2016 | November 24, 2020 |
| NCT00955721 | Terminated | Phase 1/Phase 2 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | August 2009 | July 2014 |
| NCT04057365 | Terminated | Phase 2 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | October 7, 2019 | September 25, 2022 |
| NCT04683939 | Terminated | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | January 18, 2022 | July 24, 2023 |
| NCT04163900 | Terminated | Phase 3 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | December 24, 2019 | April 5, 2022 |
| NCT00090025 | Terminated | Phase 3 | XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors | September 2004 | November 2006 |
| NCT04727541 | Terminated | Phase 2 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer | July 8, 2021 | January 5, 2022 |
| NCT00414843 | Terminated | Storage of Bile From Routine Procedures to Study Risk Factors | December 2006 | August 2015 | |
| NCT01543607 | Terminated | N/A | Endoscopic Therapy of Malignant Bile Duct Strictures | February 2012 | February 2014 |
| NCT04784520 | Terminated | Phase 2 | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer | June 22, 2021 | December 28, 2022 |
| NCT00881504 | Terminated | Phase 2 | A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma | June 2009 | December 2011 |
| NCT03291899 | Terminated | Phase 2 | Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers | January 3, 2017 | February 9, 2023 |
| NCT04692051 | Unknown status | Phase 2 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | September 1, 2019 | September 1, 2021 |
| NCT01494363 | Unknown status | Phase 2 | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer | October 2011 | December 2013 |
| NCT03873532 | Unknown status | Phase 2/Phase 3 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | July 10, 2018 | March 2022 |
| NCT01821248 | Unknown status | Phase 2 | A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis | July 23, 2013 | February 2019 |
| NCT03144856 | Unknown status | Phase 2 | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers | February 22, 2017 | March 1, 2019 |
| NCT03185988 | Unknown status | Phase 2 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | July 1, 2017 | September 2021 |
| NCT02189421 | Unknown status | N/A | Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy | April 2014 | February 2016 |
| NCT01234051 | Unknown status | Phase 2 | Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer | November 2010 | December 2013 |
| NCT01180153 | Unknown status | Phase 2 | Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) | August 2010 | August 2012 |
| NCT04300959 | Unknown status | Phase 2 | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer | January 1, 2020 | January 2022 |
| NCT04333927 | Unknown status | Phase 2 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer | June 1, 2020 | June 2024 |
| NCT05327582 | Unknown status | Phase 1/Phase 2 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | April 12, 2022 | April 30, 2024 |
| NCT05357196 | Unknown status | Phase 1/Phase 2 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | April 13, 2020 | April 28, 2023 |
| NCT03718897 | Unknown status | Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing | September 14, 2018 | September 2, 2022 | |
| NCT04571710 | Unknown status | Phase 2 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | November 1, 2020 | August 1, 2022 |
| NCT04584996 | Unknown status | CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers | October 4, 2020 | November 5, 2023 | |
| NCT04608786 | Unknown status | Phase 1 | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | February 1, 2021 | December 1, 2023 |
| NCT04637048 | Unknown status | Observational Study on Patients With Hepatobiliary Tumors | February 16, 2017 | December 1, 2023 | |
| NCT01811277 | Unknown status | Phase 2 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | July 2010 | July 2014 |
| NCT03668418 | Unknown status | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | June 1, 2018 | May 31, 2022 | |
| NCT03311789 | Unknown status | Phase 1/Phase 2 | Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs | May 1, 2017 | October 2019 |
| NCT04907864 | Unknown status | Phase 2 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE) | January 31, 2020 | June 30, 2022 |
| NCT03110484 | Unknown status | Phase 2 | Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | July 9, 2021 | June 14, 2024 |
| NCT05056116 | Unknown status | N/A | A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer | September 1, 2021 | June 2024 |
| NCT02350686 | Unknown status | Phase 2 | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | May 14, 2015 | December 2020 |
| NCT02720601 | Withdrawn | Phase 2 | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers | November 2015 | March 2020 |
| NCT03818997 | Withdrawn | Phase 2 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | December 2019 | April 2022 |
| NCT03419247 | Withdrawn | N/A | Molecular Profiling of Advanced Biliary Tract Cancers | January 1, 2020 | January 2, 2023 |
| NCT03999658 | Withdrawn | Phase 2 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | March 2023 | July 2024 |
| NCT03110510 | Withdrawn | Phase 2 | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | September 6, 2019 | September 6, 2019 |
| NCT04186156 | Withdrawn | Phase 2 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | March 5, 2020 | October 2023 |
- Disase is a (Disease Ontology)
- DOID:0080355
- Cross Reference ID (Disease Ontology)
- GARD:5924
- Cross Reference ID (Disease Ontology)
- GARD:9304
- Cross Reference ID (Disease Ontology)
- ICD10CM:C24.9
- Cross Reference ID (Disease Ontology)
- ICD9CM:156.9
- Cross Reference ID (Disease Ontology)
- MESH:D001661
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:126853008
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93688006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0005426
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0750952
- Exact Synonym (Disease Ontology)
- malignant tumour of biliary tract